Downloads

Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33(2):105–12. 2. de Baulny HO, Abadie V, Feillet F, de Parscau L. Management of phenylketonuria and hyperphenylalaninemia. J. Nutr. 2007;137(6 Suppl 1): 1561S–1563S; Discussion 1573S–1575S. 3. Novelli G, Reichardt JK. Molecular basis of disorders of human galactose metabolism: past, present, and future. Mol Genet Metab. 2000;71(1–2):62–5. 4. Heap GA, van Heel DA. Genetics and pathogenesis of coeliac disease. Semin Immunol. 2009;21(6):346–54. 5. Lactose intolerance: your guide to understanding genetic conditions. [Online]. Available: https://ghr.nlm.nih.gov/condition/lactose-intolerance. Accessed 05 June 2017. 6. Fallaize R, Macready AL, Butler LT, Ellis JA, Lovegrove JA. An insight into the public acceptance of nutrigenomic-based personalised nutrition. Nutr Res Rev. 2013;26(1):39–48. 7. San-Cristobal R, Milagro FI, Martínez JA. Future challenges and present ethical considerations in the use of personalized nutrition based on genetic advice. J Acad Nutr Diet. 2013;113(11):1447–54. 8. Ahlgren J, Nordgren A, Perrudin M, Ronteltap A, Savigny J, van Trijp H, Nordström K, Görman U. Consumers on the internet: ethical and legal aspects of commercialization of personalized nutrition. Genes Nutr. 2013;8(4):349–55. 9. Görman U, Mathers JC, Grimaldi KA, Ahlgren J, Nordström K. Do we know enough? A scientific and ethical analysis of the basis for genetic-based personalized nutrition. Genes Nutr. 2013;8(4):373–81. 10. Saukko PM, Reed M, Britten N, Hogarth S. Negotiating the boundary between medicine and consumer culture: online marketing of nutrigenetic tests. Soc Sci Med. 2010;70(5):744–53. 11. Colaiacovo M, Grimaldi KA. Personal genetics, the European regulations maze and the way out. Per Med. 2012;9(5):515–22. 12. Rozen R. Methylenetetrahydrofolate reductase: a link between folate and riboflavin? Am J Clin Nutr. 2002;76(2):301–2. 13. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China. JAMA. 2015;313(13):1325–35. 14. Corella D, Carrasco P, Sorlí JV, Estruch R, Rico-Sanz J, Martínez-González MÁ, Salas-Salvadó J, Covas MI, Coltell O, Arós F, Lapetra J, Serra-Majem L, RuizGutiérrez V, Warnberg J, Fiol M, Pintó X, Ortega-Azorín C, Muñoz MÁ, Martínez JA, Gómez-Gracia E, González JI, Ros E, Ordovás JM. Mediterranean diet reduces the adverse effect of the TCF7L2-rs7903146 polymorphism on cardiovascular risk factors and stroke incidence: a randomized controlled trial in a high-cardiovascular-risk population. Diab Care. 2013;36(11):3803–11. 15. Grimaldi KA, Look MP, Scioli GA, Clavero JC, Marinos S, Tagaris T. Personal genetics: regulatory framework in Europe from a service provider’s perspective. Eur J Hum Genet. 2011;19(4):382–8. 16. Brand A. Integrative genomics, personal-genome tests and personalized healthcare: the future is being built today. Eur J Hum Genet. 2009;17(8):977–8. 17. Borry P, van Hellemondt RE, Sprumont D, Jales CFD, Rial-Sebbag E, Spranger TM, Curren L, Kaye J, Nys H, Howard H. Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet. 2012, no. December. 2011. pp. 1–7. 18. Fears R, ter Meulen V. The perspective from EASAC and FEAM on direct-toconsumer genetic testing for health-related purposes. Eur J Hum Genet. 2013;21(7):703–7. 19. Livingstone KM, Celis-Morales C, Navas-Carretero S, San-Cristobal R, Macready AL, Fallaize R, Forster H, Woolhead C, O’Donovan CB, Marsaux CF, Kolossa S, Tsirigoti L, Lambrinou CP, Moschonis G, Godlewska M, Surwiłło A, Drevon CA, Manios Y, Traczyk I, Gibney ER, Brennan L, Walsh MC, Lovegrove JA, Saris WH, Daniel H, Gibney M, Martinez JA, Mathers JC, Food4Me Study. Effect of an Internet-based, personalized nutrition randomized trial on dietary changes associated with the Mediterranean diet: the Food4Me Study. Am. J. Clin. Nutr. 2016;104(2):288–97. 20. Celis-Morales C, Livingstone KM, Marsaux CFM, Macready AL, Fallaize R, O’Donovan CB, Woolhead C, Forster H, Walsh MC, Navas-Carretero S, SanCristobal R, Tsirigoti L, Lambrinou CP, Mavrogianni C, Moschonis G, Kolossa S, Hallmann J, Godlewska M, Surwiłło A, Traczyk I, Drevon CA, Bouwman J, van Ommen B, Grimaldi K, Parnell LD, Matthews JNS, Manios Y, Daniel H, Martinez JA, Lovegrove JA, Gibney ER, Brennan L, Saris WHM, Gibney M, Mathers JC, and Food4Me Study. Effect of personalized nutrition on healthrelated behaviour change: evidence from the Food4me European randomized controlled trial. Int J Epidemiol. 2016;46(2):578–88 21. Food4Me Gene Diet database. [Online]. Available: http://food4me.tno.nl/ database/. Accessed 05 June 2017. 22. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT-A, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FGR, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang Y-H, Khatibzadeh S, Khoo J-P, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CDH, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJC, Steenland K, Stöckl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJL, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990– 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2224–60. 23. Ferguson JF, Phillips CM, Tierney AC, Pérez-Martínez P, Defoort C, Helal O, Lairon D, Planells R, Shaw DI, Lovegrove JA, Gjelstad IM, Drevon CA, Blaak EE, Saris WH, Leszczynska-Golabek I, Kiec-Wilk B, Risérus U, Karlström B, Miranda JL, Roche HM. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr. 2010;91(3):794–801. 24. Atkinson SA. Defining the process of dietary reference intakes: framework for the United States and Canada. Am J Clin Nutr. 2011;94(2):655S–7S. 25. C. L. Taylor. Framework for DRI development: components ‘known’ and components ‘to be explored.’ 2008, 2008. [Online]. Available: https://www. nal.usda.gov/sites/default/files/fnic_uploads/Framework_DRI_Development. pdf. Accessed 05 June 2017. 26. Timotijevic L, Brown KA, Lähteenmäki L, de Wit L, Sonne A-M, Ruprich J, Rehůřková I, Jeruszka-Bielak M, Sicinska E, Brito García N, Guzzon A, Jensen BB, Shepherd R, Barnett J, Raats MM. EURRECA––a framework for considering evidence in public health nutrition policy development. Crit Rev Food Sci Nutr. 2013;53(10):1124–34. 27. Claessens M, Contor L, Dhonukshe-Rutten R, De Groot LCPGM, FairweatherTait SJ, Gurinovic M, Koletzko B, Van Ommen B, Raats MM, Van’t Veer P. EURRECA––principles and future for deriving micronutrient recommendations. Crit Rev Food Sci Nutr. 2013;53(10):1135–46. 28. Ordovas JM. Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc. 2006;106(7):1074–1081; quiz 1083. 29. Ordovas JM. Gender, a significant factor in the cross talk between genes, environment, and health. Gend Med Off J Partnersh Gender-Specific Med Columbia Univ. 2007;(4 Suppl B):S111–22. 30. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. [Online]. Available: https:// www.cdc.gov/egappreviews/. Accessed 05 June 2017. 31. Schünemann HJ, Schünemann AHJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008; 336(7653):1106–10. 32. Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, Helfand M, Ueffing E, Alonso-Coello P, Meerpohl J, Phillips B, Horvath AR, Bousquet J, Guyatt GH, Schünemann HJ. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109–16. 33. Little J, Higgins JPT, a Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N. STrengthening the REporting of Genetic Association studies (STREGA)––an extension of the STROBE statement. Eur J Clin Invest. 2009;39(4):247–66. 34. N. and A. (NDA) EFSA Panel on Dietetic Products. Scientific Opinion on principles for deriving and applying Dietary Reference Values. EFSA J. 2010; 8(3)1458. 35. M. V Relling and T. E. Klein, CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network, Clin Pharmacol Ther. 2011;89(3):464-67. 36. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JAG, Freimuth RR, Huser V, Lee MTM, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209-17. 37. CDC––Public Health Genomics|Genetic Testing|ACCE. 2010. [Online]. Available: http://www.cdc.gov/genomics/gtesting/ACCE/index.htm. Accessed 06 May 2017. 38. EuroGentest: genetic laboratories. [Online]. Available: http://www. eurogentest.org/index.php?id=139. Accessed 06 May 2017. 39. ACMG Board of Directors1. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2015;17(6):505–507. 40. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365(9469):1500–5. 41. Likelihood ratios––CEBM. [Online]. Available: http://www.cebm.net/ likelihood-ratios/. Accessed 05 June 2017. 42. Uman LS. Systematic reviews and meta-analyses. J Can Acad Child Adolesc Psychiatry = J l’Académie Can Psychiatr l'enfant l'adolescent. 2011;20(1):57–9. 43. Uncertainty assessment|European Food Safety Authority. [Online]. Available: https://www.efsa.europa.eu/en/topics/topic/uncertainty-assessment. Accessed 05 June 2017. 44. Tucker KL, Smith CE, Lai CQ, Ordovas JM. Quantifying diet for nutrigenomic studies. Annu Rev Nutr. 2013;33(1):349–71. 45. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 2005;6(4):287–98. 46. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, Totoki Y, Fujimoto A, Nakagawa H, Shibata T, Campbell PJ, Vineis P, Phillips DH, Stratton MR. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354(6312):618-22. 47. Palli D, Masala G, Peluso M, Gaspari L, Krogh V, Munnia A, Panico S, Saieva C, Tumino R, Vineis P, Garte S. The effects of diet on DNA bulky adduct levels are strongly modified by GSTM1 genotype: a study on 634 subjects. Carcinogenesis. 2004;25(4):577–84. 48. Lam TK, Gallicchio L, Lindsley K, Shiels M, Hammond E, Tao XG, Chen L, Robinson K a, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Cruciferous vegetable consumption and lung cancer risk: a systematic review. Cancer Epidemiol Biomark Prev. 2009;18(1):184–95. 49. Brennan P, Hsu CC, Moullan N, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Gemignani F, Chabrier A, Hall J, Hung RJ, Boffetta P, Canzian F. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet. 2005;366(9496):1558–60. 50. Smith CE, Ordovás JM. Fatty acid interactions with genetic polymorphisms for cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2010;13(2):139–44. 51. P. a. L. Ashfield-Watt, CH Pullin, JM Whiting, ZE Clark, SJ Moat, RG Newcombe, ML Burr, MJ Lewis, HJ Powers, IFW McDowell. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folaterich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr. 2002;76(1);180–6. 52. Wilson CP, McNulty H, Ward M, Strain JJ, Trouton TG, Hoeft BA, Weber P, Roos FF, Horigan G, McAnena L, Scott JM. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61(6):1302-8. 53. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ. 2006;333(7578):1114–7. 54. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES. Linkage disequilibrium in the human genome. Nature. 2001;411(6834):199–204. 55. Bush WS, Moore JH. Chapter 11: genome-wide association studies. PLoS Comput Biol. 2012;8(12):e1002822. 56. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–3. 57. Glenn KL, Du ZQ, Eisenmann JC, Rothschild MF. An alternative method for genotyping of the ACE I/D polymorphism. Mol Biol Rep. 2009;36(6): 1305–10. 58. Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y, Miyata T. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res. Apr. 2003;26(4):301–6. 59. Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am J Clin Nutr. 2009;89(4):1256–62. 60. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjögren M, Ling C, Eriksson K-F, Lethagen A-L, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–63. 61. Luan JA, Wong MY, Day NE, Wareham NJ. Sample size determination for studies of gene-environment interaction. Int J Epidemiol. 2001;30(5):1035–40. 62. Reddon H, Guéant J-L, Meyre D. The importance of gene-environment interactions in human obesity. Clin Sci (Lond). 2016;130(18):1571–97. 63. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82(4):806–12. 64. West AA, Caudill MA. Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010;80(4–5):319–29. 65. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer 1. Cell. 1999;59(3):602–6. 66. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005;65(6):2498-504. 67. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomark Prev. 2007;16(8):1581–6. 68. Ferrucci L, Perry JRB, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Cluett C, Fried LP, Albanes D, Corsi A-M, Cherubini A, Guralnik J, Bandinelli S, Singleton A, Virtamo J, Walston J, Semba RD, Frayling TM. Common variation in the beta-carotene 15,15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet. 2009;84(2):123–33. 69. Lietz G, Oxley A, Leung W, Hesketh J. Single nucleotide polymorphisms upstream from the β-carotene 15,15′-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr. 2012;142(1):161S–5S. 70. Caspi A, Williams B, Kim-Cohen J, Craig IW, Milne BJ, Poulton R, Schalkwyk LC, Taylor A, Werts H, Moffitt TE. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism. Proc Natl Acad Sci U S A. 2007;104(47):18860–5. 71. Steer CD, Davey Smith G, Emmett PM, Hibbeln JR, Golding J. FADS2 polymorphisms modify the effect of breastfeeding on child IQ. PLoS One. 2010;5(7):e11570. 72. Martin NW, Benyamin B, Hansell NK, Montgomery GW, Martin NG, Wright MJ, Bates TC. Cognitive function in adolescence: testing for interactions between breast-feeding and FADS2 polymorphisms. J Am Acad Child Adolesc Psychiatry. 2011;50(1):55–62.e4. 73. Parnell LD, Blokker BA, Dashti HS, Nesbeth PD, Cooper BE, Ma Y, Lee YC, Hou R, Lai CQ, Richardson K, Ordovás JM. CardioGxE, a catalog of geneenvironment interactions for cardiometabolic traits. BioData Min. 2014;7:21. 74. Zheng JS, Arnett DK, Lee YC, Shen J, Parnell LD, Smith CE, Richardson K, Li D, Borecki IB, Ordovás JM, Lai CQ. Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. PLoS One. 2013;8(10):e77442. 75. Cormier H, Tremblay BL, Paradis A-M, Garneau V, Desroches S, Robitaille J, Vohl M-C. Nutrigenomics––perspectives from registered dietitians: a report from the Quebec-wide e-consultation on nutrigenomics among registered dietitians. J Hum Nutr Diet. 2014;27(4):391–400. 76. Camp KM, Trujillo E. Position of the academy of nutrition and dietetics: nutritional genomics. J Acad Nutr Diet. 2014;114(2):299–312. 77. Kaput J. Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol. 2008;19(2):110–20. 78. Muse ED, Wineinger NE, Schrader B, Molparia B, Spencer EG, Bodian DL, Torkamani A, Topol EJ. Moving beyond clinical risk scores with a mobile app for the genomic risk of coronary artery disease. bioRxiv. 2017. https://doi.org/ 10.1101/101519. 79. FTC takes action to protect consumers from false genetic advertising claims. [Online]. Available: http://www.genomicslawreport.com/index.php/2014/07/ 03/ftc-takes-action-to-protect-consumers-from-false-genetic-advertisingclaims/. Accessed 05 June 2017. 80. Hamilton CM, Strader LC, Pratt JG, Maiese D, Hendershot T, Kwok RK, Hammond JA, Huggins W, Jackman D, Pan H, Nettles DS, Beaty TH, Farrer LA, Kraft P, Marazita ML, Ordovas JM, Pato CN, Spitz MR, Wagener D, Williams M, Junkins HA, Harlan WR, Ramos EM, Haines J. The PhenX toolkit: get the most from your measures. Am J Epidemiol. 2011;174(3):253–60. 81. Roberts JS, Gornick MC, Carere DA, Uhlmann WR, Ruffin MT, Green RC. Direct-to-consumer genetic testing: user motivations, decision making, and perceived utility of results. Public Health Genomics. 2017;20(1):36–45. 82. Gulcher J, Stefansson K. Genetic risk information for common diseases may indeed be already useful for prevention and early detection. Eur J Clin Investig. 2010;40(1):56–63. 83. Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Investig. 2010;40:64–8. 84. Ostlund RE. Phytosterols and cholesterol metabolism. Curr Opin Lipidol. 2004;15(1):37–41. 85. Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and metaanalysis. BMC Med Genet. 2009;10:15. 86. Bo S, Gambino R, Ciccone G, Rosato R, Milanesio N, Villois P, Pagano G, Cassader M, Gentile L, Durazzo M, Cavallo-perin P. Effects of TCF7L2 polymorphisms on glucose values after a lifestyle. Am J Clin Nutr. 2009;90(6):1502-8. 87. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention––wrong again? JAMA. 2008;299(17):2086–7. 88. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170(18):1622–31. 89. Tice JA. The vital amines: too much of a good thing?: comment on ‘effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality’. Arch Intern Med. 2010;170(18):1631–3. 90. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136(6 Suppl):1726S–30S. 91. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One. 2011;6(2):e16473. 92. Stampfer M, Willett W. Folate supplements for stroke prevention: targeted trial trumps the rest. JAMA. 2015;313(13):1321–2. 93. Ward M, Wilson CP, Strain JJ, Horigan G, Scott JM, McNulty H. B-vitamins, methylenetetrahydrofolate reductase (MTHFR) and hypertension. Int J Vitam Nutr Res. 2011;81(4):240–4. 94. Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, Purvis J, Scott JM. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012;95(3):766–72. 95. Horigan G, McNulty H, Ward M, Strain JJ, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. J Hypertens. 2010;28(3):478–86. 96. Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R, Weaver CM, Zeisel SH. Evidence-based criteria in the nutritional context. Nutr Rev. 2010;68(8):478–84. 97. van Ommen B, van der Greef J, Ordovas JM, Daniel H. Phenotypic flexibility as key factor in the human nutrition and health relationship. Genes Nutr. 2014;9(5):423